WuXi Biologics Completes Construction of Asia’s Largest Perfusion Biologics Manufacturing Facility Using Disposable Bioreactors

We are pleased to announce the opening of our new commercial-scale cGMP biologics perfusion manufacturing facility in the city of Wuxi, China. The $150 million commercial biologics manufacturing facility accommodates two 1000L...
WuXi Receives Merck Awards for Achieving Team Milestones

WuXi’s Partnership with Eli Lilly to Bring Novel Cardiovascular Medicines to China Named...

We are honored to be named a finalist in the 2016 Scrip Awards for Best Partnership Alliance for our collaboration with Eli Lilly to develop, manufacture, and commercialize a small-molecule drug...

WuXi AppTec Lab Testing Division and AutoGenomics Form Strategic Partnership to Introduce Advanced Molecular...

We are excited about WuXi’s Laboratory Testing Division (LTD)’s new exclusive distributor agreement with AutoGenomics, a U.S.-based molecular diagnostic BioFilmChip® microarray platform company with a current menu of 65 tests. Under the...

WuXi’s STA Subsidiary Passed Third U.S. FDA Inspection

We are pleased to announce that the small molecule active pharmaceutical ingredient (API) and advanced intermediate manufacturing facility located in Jinshan Shanghai, which is part of our subsidiary Shanghai SynTheAll Pharmaceutical...

WuXi’s STA Subsidiary Opens Operations in San Diego

We are delighted to announce that WuXi’s small-molecule process development and manufacturing subsidiary, Shanghai SynTheAll Pharmaceutical Co., Ltd. (STA), is opening operations in San Diego. STA will provide process R&D and...

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

INNOVATION THAT MATTERS